Disease index

Merkel cell carcinoma

Oncology · 2018–2026

3decisions
2medicines
3carried consumer input
11individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
retifanlimab Treatment of metastatic or recurrent, locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation. Mar 2026 Deferred 4 individuals Rare Cancers Australia · NeuroEndocrine Cancer Australia · Medical Oncology Group
retifanlimab Treatment of metastatic or recurrent, locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation. Nov 2025 Deferred 4 individuals Rare Cancers Australia · NeuroEndocrine Cancer Australia · Medical Oncology Group
avelumab Treatment of stage IV (metastatic) Merkel cell carcinoma (mMCC) in patients that have progressed following chemotherapy or who have… Jul 2018 Recommended with restriction 3 individuals Rare Cancers Australia · Unicorn Foundation · Medical Oncology Group

Who spoke

Rare Cancers Australia · Medical Oncology Group · NeuroEndocrine Cancer Australia · Unicorn Foundation

What the PBS pays

$72M in government benefit over 2024–25, across 12,301 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
avelumab $71.8M

Appraised elsewhere

NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.

TechnologyAppraisalOutcomeDate
avelumabAvelumab for untreated metastatic Merkel cell carcinoma TA691 recommended restricted 2021-04
avelumabAvelumab for treating metastatic Merkel cell carcinoma TA517 recommended restricted 2018-04

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.